Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial - 28/04/22
, Stefanie Weigel, ProfMD a, *, Joachim Gerß, Dr rer nat b, Hans-Werner Hense, ProfMD c, Alexander Sommer, Dipl Ing a, Miriam Krischke, Dr rer nat d, Laura Kerschke, Dr rer medic bon behalf of the
for the TOSYMA Screening Trial Study Group†
Summary |
Background |
Two dimensional (2D) full-field digital mammography is the current standard of breast cancer screening. Digital breast tomosynthesis generates pseudo-three dimensional datasets of the breast from which synthesised 2D (s2D) mammograms can be reconstructed. This innovative approach reduces the likelihood of overlapping breast tissues that can conceal features of malignancy. We aimed to compare digital breast tomosynthesis plus s2D mammography with digital screening mammography for the detection of invasive breast cancer.
Methods |
TOSYMA was a randomised, open-label, superiority trial done at 17 screening units in two federal states of Germany. Eligible participants were women aged 50–69 years who had been invited to participate in a population-wide, quality-controlled mammography screening programme. Women were randomly assigned (1:1) to digital breast tomosynthesis plus s2D mammography or digital mammography alone using block randomisation (block size of 32), stratified by site. The primary endpoints were the detection rate of invasive breast cancer and invasive interval cancer rate at 24 months, analysed in the modified full analysis set, which included all randomly assigned participants who underwent either type of screening examination. Ten examinations, corresponding to a second study participation, were excluded. Analyses were done according to the intention-to-treat principle. Interval cancer rates will be reported in the follow-up study. Safety was assessed in the as-treated population, which included all participants who were randomly assigned. This trial is registered with ClinicalTrials.gov, NCT03377036, and is closed to accrual.
Findings |
Between July 5, 2018, and Dec 30, 2020, 99 689 women were randomly assigned to digital breast tomosynthesis plus s2D mammography (n=49 804) or digital mammography (n=49 830). Invasive breast cancers were detected in 354 of 49 715 women with evaluable primary endpoint data in the digital breast tomosynthesis plus s2D group (detection rate 7·1 cases per 1000 women screened) and in 240 of 49 762 women in the digital mammography group (4·8 cases per 1000 women screened; odds ratio 1·48 [95% CI 1·25–1·75]; p<0·0001). Adverse events and device deficiencies were rare (six adverse events in each group; 23 device deficiencies in the digital breast tomosynthesis plus s2D group vs five device deficiencies in the digital mammography group) and no serious adverse events were reported.
Interpretation |
The results from this study indicate that the detection rate for invasive breast cancer was significantly higher with digital breast tomosynthesis plus s2D mammography than digital mammography alone. Evaluation of interval cancer rates in the follow-up study will further help to investigate incremental long-term benefits of digital breast tomosynthesis screening.
Funding |
Deutsche Forschungsgemeinschaft (German Research Foundation).
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 5
P. 601-611 - mai 2022 Retour au numéro
Article précédent
- Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study
- Sean McPhail, Ruth Swann, Shane A Johnson, Matthew E Barclay, Hazem Abd Elkader, Riaz Alvi, Andriana Barisic, Oliver Bucher, Gavin R C Clark, Nicola Creighton, Bolette Danckert, Cheryl A Denny, David W Donnelly, Jeff J Dowden, Norah Finn, Colin R Fox, Sharon Fung, Anna T Gavin, Elba Gomez Navas, Steven Habbous, Jihee Han, Dyfed W Huws, Christopher G C A Jackson, Henry Jensen, Bethany Kaposhi, S Eshwar Kumar, Alana L Little, Shuang Lu, Carol A McClure, Bjørn Møller, Grace Musto, Yngvar Nilssen, Nathalie Saint-Jacques, Sabuj Sarker, Luc te Marvelde, Rebecca S Thomas, Robert J S Thomas, Catherine S Thomson, Ryan R Woods, Bin Zhang, Georgios Lyratzopoulos, ICBP Module 9 Emergency Presentations Working Group, Brooke Filsinger, Katharina Forster, Leon May, David S Morrison, A. Ffion Thomas, Janet L Warlow, Hui You
- Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
- Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross-Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwenaëlle Gravis, Nadine Houede, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, Nicolas Doumerc, Philippe Paparel, Jean-Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, Géraldine Pignot, Elena Braychenko, Stefano Caruso, Cheng-Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougouïn, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman-Rossi, Wolf Herman Fridman, Catherine Sautès-Fridman, Stéphane Oudard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?